Back to Atlas
APotentially durableResearch-only / high verification need
CMP-0037
Investigational oncology
CUDC-907 / Fimepinostat
Senolytic / PI3K-HDAC
Preclinical senolytic/oncology research positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- Dual PI3K/HDAC inhibition induces apoptosis and may target senescent-cell survival
- Primary market use
- Senolytic / oncology research
Pharmacology
- Molecular weight (Da)
- 508.56
- Oral bioavailability
- Orally available investigational drug
- Half-life
- ~6-10 h; not consistently disclosed
- Route tags
- Oral
- Evidence level
- Clinical/Preclinical
- Clinical status
- Investigational oncology
- Value-for-money score
- 3 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Oral but oncology-grade inhibitor; value limited outside disease context